All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Visual abstract | Auto-HSCT after a rituximab/ibrutinib/Ara-c containing induction in generalized mantle cell lymphoma: TRIANGLE trial

Jun 11, 2024
Learning objective: After reading this visual abstract, learners will be able to cite a new development in the treatment of mantle cell lymphoma.

The Lymphoma Hub is pleased to present a visual abstract summarizing results from the phase III TRIANGLE trial (NCT02858258) assessing the safety and efficacy of the addition of ibrutinib, a Bruton’s tyrosine kinase inhibitor, to standard immunochemotherapy with or without autologous hematopoietic stem cell transplantation (auto-HSCT) in younger patients with mantle cell lymphoma. Results from this trial were published by Dreyling et al.1 in The Lancet

The addition of ibrutinib to standard immunochemotherapy improved outcomes; however, toxicity was increased when ibrutinib was given after auto-HSCT.1 Whether auto-HSCT is beneficial with ibrutinib-based treatment is yet to be determined.1


Visual abstract

To download this visual abstract, click below.

Download here

  1. Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. 2024. Online ahead of print. DOI: 10.1016/S0140-6736(24)00184-3.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox